| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2011-01-11 | biosimilar rituximab | rheumatoid arthritis | 2 | Sandoz (Switzerland) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2011-01-10 | BC-3781 | acute bacterial skin and skin structure infections (ABSSSI) | 2 | Nabriva Therapeutics (Austria) | Infectious diseases |
| 2011-01-07 | 4SC-203 | 1 | 4SC (Germany) | Cancer Oncology | |
| 2011-01-03 | Nalmefene | alcohol dependence | 3 | Lundbeck (Denmark) | CNS diseases |
| 2010-11-22 | SYL040012 | ocular hypertension., glaucoma | 1-2 | Sylentis (Spain) | Ophtalmological diseases |
| 2010-11-01 | galunisertib (LY2157299) | hepatocellular carcinoma | 2 | Eli Lilly (USA - IN) | Cancer - Oncology |
| 2010-10-12 | galunisertib | glioma | 1b-2a | Eli Lilly (USA - IN) | Cancer - Oncology |
| 2008-03-05 | aglatimagene besadenovec (AdV-tk) followed by valacyclovir | glioma | 1 | Advantagene (USA - MA) | Cancer - Oncology |
| 2007-12-27 | aglatimagene besadenovec (AdV-tk) followed by valacyclovir | glioma | 2a | Advantagene (USA - MA) | Cancer - Oncology |
